SynthesisJournal of global health2026
National, regional, and provincial prevalence of age-related macular degeneration in China in 2020: an updated systematic review and modelling study.
Synthesis in Journal of global health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The burden of age-related macular degeneration (AMD) has steadily increased in recent decades. We aimed to estimate the prevalence of AMD, including its subtypes, among individuals aged 40-89 years in China. Methods: We conducted an updated literature search in the CNKI, Wanfang, Chinese Science and Technology Journal Database, PubMed, Embase, and MEDLINE for studies published between 27 June 2016 and 30 July 2024 that reported on the prevalence of AMD in China. We also included data from the 2017 China AMD Study. We utilised a multi-level mixed-effects meta-regression model to estimate age- and sex-specific prevalence of any AMD and its subtypes at the national level. For any AMD, we additionally conducted random-effects meta-analyses to pool odds ratios for associated factors, after which we incorporated these estimates into an associated factor-based model to estimate prevalence at regional and provincial levels. Results: We included 40 articles, of which 24 contributed data for modelling analysis. The estimated national prevalence in China in 2020 was 4.70% (95% CI = 3.40, 6.46) for any AMD, 4.06% (95% CI = 2.92, 5.60) for early AMD, and 0.64% (95% CI = 0.48, 0.86) for late AMD, including 0.30% (95% CI = 0.25, 0.37) for geographic atrophy and 0.34% (95% CI = 0.23, 0.49) for neovascular AMD. These corresponded to 32.42 million cases (95% CI = 23.43, 44.54) with any AMD, 28.00 million (95% CI = 20.15, 38.61) with early AMD, 4.42 million (95% CI = 3.28, 5.93) with late AMD, 2.09 million (95% CI = 1.71, 2.52) with geographic atrophy, and 2.33 million (95% CI = 1.57, 3.41) with neovascular AMD. Regionally, the highest prevalence and number of cases was observed in Southwest China (5.95%; 95% CI = 4.48, 7.81) and South Central China (10.68 million; 95% CI = 7.60, 14.82), respectively. At the provincial level, Hainan and Guangdong exhibited the highest prevalence (7.64%; 95% CI = 4.61, 12.22) and the largest number of individuals affected (3.50 million; 95% CI = 2.34, 5.13), respectively. Conclusions: We observed a substantial burden of AMD in Mainland China, with variations across subtypes, regions, and provinces. These findings underscore a need for targeted public health strategies to address AMD in the context of ageing. Registration: PROSPERO: CRD420251080685.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.